Endotelio

  • 文章类型: Journal Article
    血压变异性(BPV)增加与更高的心血管风险相关。到目前为止,尚未研究BPV与高血压患者的液体状态之间的关联。本研究的目的是确定原发性高血压患者中液体平衡对BPV的贡献以及对内皮和心脏功能的影响。
    这是一项对原发性高血压患者进行为期一年随访的前瞻性干预研究。通过身体成分监测器进行的体积状态测量,动态血压(BP)监测,在入组时和第12天进行超声心动图和颈动脉内中膜厚度(CIMT)测量。在使用利尿剂治疗的试验期间,两组中的一组患者保持阴性水分。其他组的患者在入组时呈正水合(高容量),根据血压监测,添加或强化了除利尿剂(血管扩张剂)以外的抗高血压药物。平均真实变异性(ARV)指数用于确定BPV的预后意义。
    研究人群包括50名患者,平均年龄为54.5±8.8岁。在为期一年的随访结束时,阴性水合组的患者血压明显降低,CIMT,左心室质量指数(LVMI)和收缩和舒张性ARV。体重增加和收缩压升高是高收缩期ARV的主要危险因素。CIMT和LVMI改善的患者被认为是靶器官损害(TOD)恢复存在。在负水合组中,试验期间TOD显著降低。在TOD恢复的患者中,BPV明显更降低,如收缩压和舒张压。与TOD相关的重要危险因素是24h收缩压,白天和夜间舒张性ARV和夜间舒张性BP。
    在既定治疗或强化利尿剂治疗中加入利尿剂,并使患者保持阴性水合状态,可在随访的第12个月时降低BPV。更多的体重增加和更高的收缩压是高收缩期ARV的主要危险因素,但不是血容量过高.BPV,尤其是舒张性ARV,与TOD显著相关。
    Increased blood pressure variability (BPV) is associated with higher cardiovascular risk. The association between BPV and fluid status in hypertensive patients has not been investigated so far. The aim of the present study was to determine the contribution of fluid balance to BPV and impact on endothelial and cardiac functions among primary hypertensive patients.
    This is a prospective interventional study conducted in primary hypertensive patients with one-year follow-up. Volume status measurements by a body composition monitor, ambulatory blood pressure (BP) monitoring, echocardiographic and carotid intima-media thickness (CIMT) measurements were performed at enrollment and at twelfth. Patients in one of the two groups were kept negative hydrated during trial with diuretic treatment. Patients in other group were positively hydrated (hypervolemic) at enrollment, antihypertensive drugs other than diuretics (vasodilator agents) were added or intensified according to the BP monitoring. Average real variability (ARV) index was used for establishing the prognostic significance of BPV.
    The study population consisted of 50 patients with a mean age of 54.5±8.8 years. At the end of one-year follow-up, patients in negative hydrated group were found to have significantly lower BP, CIMT, left ventricle mass index (LVMI) and systolic and diastolic ARV. More weight gain and higher systolic BP were major risk factors of high systolic ARV. Patients who have improvement in CIMT and LVMI were considered as target organ damage (TOD) recovery present. In negatively hydrated group, TOD significantly reduced during trial. In patients who have TOD recovery, BPV significantly more reduced like systolic and diastolic BP. Significant risk factors associated with the presence of TOD were 24h systolic BP and daytime and night time diastolic ARV and night time diastolic BP.
    Addition of diuretic to established treatment or intensified diuretic treatment and keeping patients in negative hydration status resulted in reduction in BPV at twelfth month of follow-up. More weight gain and higher systolic BP are major risk factors of high systolic ARV, but not hypervolemia. BPV, especially diastolic ARV, was significantly associated with TOD.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    糖尿病的患病率在上个世纪增加,估计有45%的患者未被诊断。在南美洲,糖尿病和慢性肾脏病(CKD)的患病率增加,各国在获得透析方面存在巨大差距。在厄瓜多尔,它是死亡的主要原因之一,主要位于太平洋沿岸的省份。开始透析的最大单一原因是糖尿病肾病(DN)。即使使用DN的最佳治疗选择,蛋白尿和终末期CKD的残余风险仍然很高。在这次审查中,我们指出了该问题在全球和我们地区的重要性。我们分析了相关的细胞和分子研究,这些研究说明了肾小球事件在DN发展和进化以及胰岛素抵抗中的重要意义。我们包括基本的解剖学,病理生理和临床概念,特别关注血管生成因子如血管内皮生长因子(VEGF-A)的作用及其与胰岛素受体的关系,一氧化氮合酶(eNOS)和血管生成素的内皮同工型。我们还提出了我们认为具有治疗潜力的各种途径。更深入的研究VEGF-A和血管生成素,肾小球VEGF抵抗的状态,VEGF受体2/nephrin的关系,VEGF/胰岛素受体/nephrin以及肾小球水平的VEGF/eNOS-NO的关系可以为DN这一紧迫的世界问题提供解决方案,并产生新的治疗替代方案。
    The prevalence of diabetes mellitus increased during the last century and it is estimated that 45% of the patients are not diagnosed. In South America the prevalence of diabetes and chronic kidney disease (CKD) increased, with a great disparity among the countries with respect to access to dialysis. In Ecuador it is one of the main causes of mortality, principally in the provinces located on the coast of the Pacific Ocean. The greatest single cause of beginning dialysis is diabetic nephropathy (DN). Even using the best therapeutic options for DN, the residual risk of proteinuria and of terminal CKD remains high. In this review we indicate the importance of the problem globally and in our region. We analyse relevant cellular and molecular studies that illustrate the crucial significance of glomerular events in DN development and evolution and in insulin resistance. We include basic anatomical, pathophysiological and clinical concepts, with special attention to the role of angiogenic factors such as the vascular endothelial growth factor (VEGF-A) and their relationship to the insulin receptor, endothelial isoform of nitric oxide synthase (eNOS) and angiopoietins. We also propose various pathways that have therapeutic potential in our opinion. Greater in-depth study of VEGF-A and angiopoietins, the state of glomerular VEGF resistance, the relationship of VEGF receptor 2/nephrin, VEGF/insulin receptors/nephrin and the relationship of VEGF/eNOS-NO at glomerular level could provide solutions to the pressing world problem of DN and generate new treatment alternatives.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    目标:地中海饮食,富含多酚,已经证明对心脏有保护作用.然而,所涉及的机制仍然未知。我们研究了在临床相关实验模型中补充富含多酚的石榴提取物是否对冠状动脉功能产生有益影响,并表征了潜在的机制。
    方法:猪饲喂10天的正常胆固醇血症或高胆固醇血症饮食。给一半的动物补充625mg/天的石榴提取物(Pomanox;200mgpunicalagins/天)。冠状动脉对不断增加剂量的血管活性药物的反应(乙酰胆碱,钙离子载体,使用血流多普勒测量硝普钠)和L-NG-单甲基精氨酸(内皮型一氧化氮合酶抑制剂)。Akt/内皮型一氧化氮合酶轴激活,单核细胞趋化蛋白-1表达,冠状动脉中的氧化脱氧核糖核酸损伤,并评估了脂蛋白对氧化的抵抗力。
    结果:在血脂异常的动物中,补充Pomanox可预防饮食引起的内皮舒张损伤,在用乙酰胆碱和/或钙离子载体刺激后达到与正常胆固醇动物相当的血管舒张值。这些有益作用与血管Akt/内皮一氧化氮合酶激活和较低的单核细胞趋化蛋白1表达有关。补充Pomanox可降低全身氧化应激(较高的高密度脂蛋白抗氧化能力和较高的低密度脂蛋白抗氧化能力)和冠状动脉脱氧核糖核酸损伤。无论补充Pomanox,正常胆固醇血症的动物都会引起类似的药物相关血管舒张。所有动物对硝普钠均表现出相似的血管舒张反应,L-NG-单甲基精氨酸减弱了除硝普钠外的所有血管舒张反应。
    结论:补充Pomanox可通过激活Akt/内皮型一氧化氮合酶通路并有利地抵消血管炎症和氧化损伤来阻止高脂血症诱导的冠状动脉内皮功能障碍。
    OBJECTIVE: The Mediterranean diet, rich in polyphenols, has shown to be cardioprotective. However the mechanisms involved remain unknown. We investigated whether supplementation with a pomegranate extract rich in polyphenols renders beneficial effects on coronary function in a clinically relevant experimental model and characterized the underlying mechanisms.
    METHODS: Pigs were fed a 10-day normocholesterolemic or hypercholesterolemic diet. Half of the animals were given a supplement of 625 mg/day of a pomegranate extract (Pomanox; 200 mg punicalagins/day). Coronary responses to escalating doses of vasoactive drugs (acetylcholine, calcium ionophore, and sodium nitroprusside) and L-NG-monomethylarginine (endothelial nitric oxide-synthase inhibitor) were measured using flow Doppler. Akt/endothelial nitric oxide-synthase axis activation, monocyte chemoattractant protein-1 expression, oxidative deoxyribonucleic acid damage in the coronary artery, and lipoprotein resistance to oxidation were evaluated.
    RESULTS: In dyslipidemic animals, Pomanox supplementation prevented diet-induced impairment of endothelial relaxation, reaching vasodilatory values comparable to normocholesterolemic animals upon stimulation with acetylcholine and/or calcium ionophore. These beneficial effects were associated with vascular Akt/endothelial nitric oxide-synthase activation and lower monocyte chemoattractant protein-1 expression. Pomanox supplementation reduced systemic oxidative stress (higher high-density lipoprotein-antioxidant capacity and higher low-density lipoprotein resistance to oxidation) and coronary deoxyribonucleic acid damage. Normocholesterolemic animals elicited similar drug-related vasodilation regardless of Pomanox supplementation. All animals displayed a similar vasodilatory response to sodium nitroprusside and L-NG-monomethylarginine blunted all vasorelaxation responses except for sodium nitroprusside.
    CONCLUSIONS: Pomanox supplementation hinders hyperlipemia-induced coronary endothelial dysfunction by activating the Akt/endothelial nitric oxide-synthase pathway and favorably counteracting vascular inflammation and oxidative damage.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号